Invion (DE:7C8)
FRANKFURT:7C8
7C8 Stock Chart & Stats
€0.03
-€0.03(-19.10%)
At close: 4:00 PM EST
€0.03
-€0.03(-19.10%)
Day’s Range― - ―
52-Week Range€0.02 - €0.09
Previous CloseN/A
Volume0.00
Average Volume (3M)14.00
Market Cap
€2.83M
Enterprise Value€4.76M
Total Cash (Recent Filing)€137.54K
Total Debt (Recent Filing)€627.68K
Price to Earnings (P/E)―
Beta-4.93
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding96,965,320
10 Day Avg. Volume40
30 Day Avg. Volume14
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.96
Price to Sales (P/S)0.00
P/FCF Ratio-2.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtA debt-free balance sheet materially reduces fixed interest obligations and financial distress risk, giving management flexibility to prioritize R&D and partnerships. Over 2–6 months this lowers bankruptcy risk and improves options for fundraising structure and timing.
Partner-funded R&D & LicensingRelying on development funding and milestone/licensing payments transfers development cost risk to partners and creates non‑dilutive or milestone-based cash inflows. Structurally this supports continuing operations and program advancement despite weak internal sales.
Proprietary PDT Tech & Research TiesOwning proprietary photodynamic‑therapy IP and formal research collaborations builds a durable competitive edge and external validation pipeline. These assets support licensing potential, barrier to entry for competitors, and long‑term commercialization pathways.
Bears Say
Revenue Collapse And Widening LossesA drop to zero reported revenue with a materially larger net loss signals failure to monetize earlier programs and undermines the business model. Over months this increases dependency on external funding and erodes investor confidence, hampering strategic execution.
Persistent Negative Cash Flow / Cash BurnConsistent negative operating and free cash flow forces repeated external financing or partner dependence. This structurally raises dilution or financing risk, limits discretionary spending on trials/commercialization, and shortens runway absent new funding.
Shrinking Equity And Asset BaseRapid erosion of shareholder equity and declining asset totals reduce financial flexibility and the buffer to absorb future losses. Over the medium term this impairs collateral capacity, heightens vulnerability to shocks, and raises costs of any debt or partnership financing.
Invion News
7C8 FAQ
What was Invion’s price range in the past 12 months?
Invion lowest stock price was €0.02 and its highest was €0.09 in the past 12 months.
What is Invion’s market cap?
Invion’s market cap is €2.83M.
When is Invion’s upcoming earnings report date?
Invion’s upcoming earnings report date is Aug 27, 2026 which is in 78 days.
How were Invion’s earnings last quarter?
Invion released its earnings results on Feb 26, 2026. The company reported -€0.026 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.026.
Is Invion overvalued?
According to Wall Street analysts Invion’s price is currently Overvalued.
Does Invion pay dividends?
Invion does not currently pay dividends.
What is Invion’s EPS estimate?
Invion’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invion have?
Invion has 96,965,320 shares outstanding.
What happened to Invion’s price movement after its last earnings report?
Invion reported an EPS of -€0.026 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Invion?
Currently, no hedge funds are holding shares in DE:7C8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.00%
12-Months-Change
Fundamentals
Return on Equity
-150.48%
Trailing 12-Months
Asset Growth
-37.10%
Trailing 12-Months
Company Description
Invion
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma. The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft technology across a broad spectrum of cancer treatments. Moreover, a dedicated research agreement with the Peter MacCallum Cancer Centre facilitates pre-clinical and in-vitro investigations into Invion's IVX-PDT for ano-genital cancers, such as penile and anal cancers. The firm was established in 2000 and is headquartered in Melbourne, Australia.
Technical Analysis
Percheron Therapeutics
―
Argent Biopharma
―
Medical Developments International Limited
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―
Options Prices
Currently, No data available
---